BACKGROUND: Milan and University of California San Francisco (UCSF) Criteria have been used for selection of patients with hepatocellular carcinoma (HCC) for liver transplantation (LTx). The aims of this study were to analyse the results of LTx for HCC in Australia and New Zealand with emphasis on the effects of discordance between pre-LTx radiological and post-LTx pathological staging. METHODS: A total of 186 LTx for HCC carried out between July 1985 and August 2003 were included. Patients were categorized according to the Milan and UCSF Criteria. RESULTS: The median follow-up was 6.55 years (range 2.96-20.93 years). Pre-LTx factors associated with better survival include tumour size < or = 5 cm, number of tumours < or = 3, staging within Milan and UCSF Criteria and more recent transplantation (1996-2003). In all, 14 patients had a pre-LTx stage outside the Milan but within the UCSF Criteria. One- and 5-year patient survival rates were, respectively, 88% and 74% within the Milan Criteria, and 87% and 73% within the UCSF Criteria. Vascular invasion, capsular invasion, lymph node invasion and pathological stage outside UCSF Criteria were associated with poor outcome. Of patients within the Milan and UCSF Criteria pre-LTx, 24% and 18%, respectively, were outside the same criteria post-LTx. These patients had poorer survival rates. CONCLUSIONS: The use of the UCSF Criteria in this cohort increased the number of patients eligible for LTx without compromising 5-year survival rates. Patients whose explant tumours were outside the Milan or UCSF Criteria had poorer outcomes compared with those whose explants remained within these criteria.
BACKGROUND: Milan and University of California San Francisco (UCSF) Criteria have been used for selection of patients with hepatocellular carcinoma (HCC) for liver transplantation (LTx). The aims of this study were to analyse the results of LTx for HCC in Australia and New Zealand with emphasis on the effects of discordance between pre-LTx radiological and post-LTx pathological staging. METHODS: A total of 186 LTx for HCC carried out between July 1985 and August 2003 were included. Patients were categorized according to the Milan and UCSF Criteria. RESULTS: The median follow-up was 6.55 years (range 2.96-20.93 years). Pre-LTx factors associated with better survival include tumour size < or = 5 cm, number of tumours < or = 3, staging within Milan and UCSF Criteria and more recent transplantation (1996-2003). In all, 14 patients had a pre-LTx stage outside the Milan but within the UCSF Criteria. One- and 5-year patient survival rates were, respectively, 88% and 74% within the Milan Criteria, and 87% and 73% within the UCSF Criteria. Vascular invasion, capsular invasion, lymph node invasion and pathological stage outside UCSF Criteria were associated with poor outcome. Of patients within the Milan and UCSF Criteria pre-LTx, 24% and 18%, respectively, were outside the same criteria post-LTx. These patients had poorer survival rates. CONCLUSIONS: The use of the UCSF Criteria in this cohort increased the number of patients eligible for LTx without compromising 5-year survival rates. Patients whose explant tumours were outside the Milan or UCSF Criteria had poorer outcomes compared with those whose explants remained within these criteria.
Entities:
Keywords:
Milan Criteria; UCSF Criteria; hepatectomy; liver cancer
Authors: U Baccarani; G L Adani; C Avellini; D Lorenzin; G Currò; A Beltrami; A Pasqualucci; V Bresadola; A Risaliti; P L Viale; C A Beltrami; F Bresadola Journal: Transplant Proc Date: 2006-05 Impact factor: 1.066
Authors: Shimul A Shah; Jensen C C Tan; Ian D McGilvray; Mark S Cattral; Sean P Cleary; Gary A Levy; Paul D Greig; David R Grant Journal: Transplantation Date: 2006-06-27 Impact factor: 4.939
Authors: Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton Journal: Liver Transpl Date: 2006-08 Impact factor: 5.799
Authors: Timothy M Pawlik; Keith A Delman; Jean-Nicolas Vauthey; David M Nagorney; Irene Oi-Lin Ng; Iwao Ikai; Yoshio Yamaoka; Jacques Belghiti; Gregory Y Lauwers; Ronnie T Poon; Eddie K Abdalla Journal: Liver Transpl Date: 2005-09 Impact factor: 5.799
Authors: Francis Y Yao; Ryutaro Hirose; Jeanne M LaBerge; Timothy J Davern; Nathan M Bass; Robert K Kerlan; Raphael Merriman; Sandy Feng; Chris E Freise; Nancy L Ascher; John P Roberts Journal: Liver Transpl Date: 2005-12 Impact factor: 5.799
Authors: Marcos Vinicius Perini; Graham Starkey; Michael A Fink; Ramesh Bhandari; Vijayaragavan Muralidharan; Robert Jones; Christopher Christophi Journal: World J Hepatol Date: 2015-01-27
Authors: Savio G Barreto; Simone I Strasser; Geoffrey W McCaughan; Michael A Fink; Robert Jones; John McCall; Stephen Munn; Graeme A Macdonald; Peter Hodgkinson; Gary P Jeffrey; Bryon Jaques; Michael Crawford; Mark E Brooke-Smith; John W Chen Journal: Cancers (Basel) Date: 2022-06-03 Impact factor: 6.575
Authors: Jorge Henrique Bento de Sousa; Igor Lepski Calil; Francisco Tustumi; Douglas da Cunha Khalil; Guilherme Eduardo Gonçalves Felga; Rafael Antonio de Arruda Pecora; Marcio Dias de Almeida Journal: Transl Gastroenterol Hepatol Date: 2021-01-05
Authors: Uta Herden; Wenzel Schoening; Johann Pratschke; Steffen Manekeller; Andreas Paul; Richard Linke; Thomas Lorf; Frank Lehner; Felix Braun; Dirk L Stippel; Robert Sucher; Hartmut Schmidt; Christian P Strassburg; Markus Guba; Marieke van Rosmalen; Xavier Rogiers; Undine Samuel; Gerhard MSc Schön; Bjoern Nashan Journal: Can J Gastroenterol Hepatol Date: 2019-03-05
Authors: Marco Biolato; Giuseppe Marrone; Luca Miele; Antonio Gasbarrini; Antonio Grieco Journal: World J Gastroenterol Date: 2017-05-14 Impact factor: 5.742